Psilera Bioscience is one of the many young companies trying to make new psychoactive substances.
Psilera Bioscience
The company is currently in the University of South Florida’s TBTI Incubator program.
Psilera has raised a total of U$2.5 million in funding over one round. This was a seed round raised on July 1 2021.
“Reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics.”
Key Staff
- Chris Witowski – Founder & CEO
- Jack von Salm – Founder & CSO
News
- New Psylocybin Company Enters The Market (Green Market Report, July 2020)
- Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies (press release, July 2020)
Activities
B2B
Biotech
Drug Discovery
Topics of Interest
Alcohol Use Disorder
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates